Pfizer's (PFE.US) $43 billion Seagen (SGEN.US) deal wins unconditional EU approval. As it was concluded by European lawmakers, deal wouldn't raise competition concerns or higher prices for oncology drugs.
Source: xStation5
Paramount Skydance shares under pressure after S&P warning
Broadcom as the Last of the Big Tech. What Can Markets Expect from the Earnings?
Nvidia Faces New H200 Limits in China
US Open: Wall Street in Blood